Controversy reportedly erupted at a European cardiovascular society conference this week after a prominent cardiologist accused the study’s investigators of manipulating the trial to skew the results. Five-year data from the Excel trial, released last month at the Transcatheter Cardiovascular Therapies conference, showed that percutaneous coronary intervention was as good as coronary artery bypass grafts […]
TCT 2019
TCT 2019: Boston Scientific slides on Acurate Neo TMVR trial miss
The Acurate Neo replacement heart valve being developed by Boston Scientific (NYSE:BSX) failed to show non-inferiority in a head-to-head comparison with the Sapien 3 valve made by Edwards Lifesciences (NYSE:EW), according to study data released at the annual Transcatheter Cardiovascular Technologies conference in San Francisco. The 739-patient Scope I study randomized increased-risk patients to either Acurate Neo […]
TCT 2019: Medtronic’s Resolute Onyx non-inferior to Biosensors Biofreedom stent
A study comparing the Resolute Onyx drug-eluting stent from Medtronic (NYSE:MDT) and the BioFreedom stent made by Biosensors International (PINK:BSNRY) showed the Medtronic device to be non-inferior in patients on a one-month dual anti-platelet therapy regimen, according to results presented yesterday at the annual Transcatheter Cardiovascular Technologies conference in San Francisco. Medtronic launched the 2,000-patient study […]